Michael Kozal
Yale University
H-index: 40
North America-United States
Top articles of Michael Kozal
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Rate of response to initial antiretroviral therapy according to level of pre‐existing HIV‐1 drug resistance detected by next‐generation sequencing in the strategic timing of … | HIV medicine | Alessandro Cozzi‐Lepri David Dunn Anna Tostevin Rasmus L Marvig Marc Bennedbæk | 2024/2/1 |
365. Durable efficacy and robust CD4+ T-cell count improvement observed across age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug … | Open Forum Infectious Diseases | Alftan Dyson Judith A Aberg Jean-Michel Molina Isabel Cassetti Michael Kozal | 2023/12 |
Fostemsavir: a first-in-class HIV-1 attachment inhibitor | Philip M Grant Michael J Kozal | 2022/1/1 | |
Week 96 genotypic and phenotypic results of the fostemsavir phase 3 BRIGHTE study in heavily treatment-experienced adults living with multidrug-resistant HIV-1 | Antimicrobial agents and chemotherapy | Margaret Gartland Pedro Cahn Edwin DeJesus Ricardo Sobhie Diaz Robert Grossberg | 2022/6/21 |
Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals | Aids | Brian Moldt Huldrych F Günthard Kimberly A Workowski Susan J Little Joseph J Eron | 2022/2/1 |
ANÁLISE DE SUBGRUPO DOS RESULTADOS DE EFICÁCIA E SEGURANÇA DA SEMANA 96 AVALIANDO O FOSTEMSAVIR EM PARTICIPANTES INFECTADOS POR HIV‐1 EXTENSAMENTE EXPERIMENTADOS AO TRATAMENTO … | Peter Ackerman Judith Aberg Jean‐Michael Molina Isabel Cassetti Michael Kozal | 2021 | |
Fostemsavir for the treatment of HIV | Nikhil Seval Cynthia Frank Michael Kozal | 2021/8/3 | |
Fostemsavir in Heavily Treatment-Experienced Individuals Living with HIV-1: Insights from the Phase 3 BRIGHTE Study | Journal of AIDS and HIV Treatment | Max Lataillade Peter Ackerman Till Schoofs Andrew Clark Michael Kozal | 2021/6/21 |
Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1 | AIDS | Peter Ackerman Melanie Thompson Jean-Michel Molina Judith Aberg Isabel Cassetti | 2021/6/1 |
Transmitted HIV‐1 drug resistance in a large international cohort using next‐generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study | HIV medicine | John D Baxter David Dunn Anna Tostevin Rasmus L Marvig Marc Bennedbæk | 2021/5 |
SARS-CoV-2 detection in setting of viral swab scarcity: are MRSA swabs and viral swabs equivalent?(preprint) | Daneil G Federman Shaili Gupta Gary Stack Sheldon M Campbell David R Peaper | 2020 | |
Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders | Journal of medical virology | Michael Fuchs Alexander Monto Norbert Bräu Mariem Charafeddine Warren Schmidt | 2020/12 |
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study | The Lancet HIV | Max Lataillade Jacob P Lalezari Michael Kozal Judith A Aberg Gilles Pialoux | 2020/11/1 |
SARS-CoV-2 detection in setting of viral swabs scarcity: Are MRSA swabs and viral swabs equivalent? | Plos one | Daniel G Federman Shaili Gupta Gary Stack Sheldon M Campbell David R Peaper | 2020/8/5 |
Fostemsavir in adults with multidrug-resistant HIV-1 infection | New England Journal of Medicine | Michael Kozal Judith Aberg Gilles Pialoux Pedro Cahn Melanie Thompson | 2020/3/26 |
